Oruka Therapeutics annual working capital
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Oruka Therapeutics Working Capital Growth & History (ORKA)
Oruka Therapeutics's working capital was $328.5M for fiscal 2025.
View full Oruka Therapeutics company overviewOruka Therapeutics annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $328.5M | −$35.3M | −9.71% |
| 2024 | 2024-12-31 | $363.8M | $326.9M | +884.51% |
| 2023 | 2023-12-31 | $37.0M | −$4.6M | −11.10% |
| 2022 | 2022-12-31 | $41.6M | −$9.4M | −18.37% |
| 2021 | 2021-12-31 | $50.9M | $4.5M | +9.58% |
| 2020 | 2020-12-31 | $46.5M | $38.9M | +515.16% |
| 2019 | 2019-12-31 | $7.6M | $1.6M | +26.24% |
| 2018 | 2018-12-31 | $6.0M | −$4.2M | −41.50% |
| 2017 | 2017-12-31 | $10.2M | −$8.8M | −46.30% |
| 2016 | 2016-12-31 | $19.0M | −$18.4M | −49.08% |
| 2015 | 2015-12-31 | $37.4M | $23.3M | +165.33% |
| 2014 | 2014-12-31 | $14.1M | −$1.3M | −8.58% |
| 2013 | 2013-12-31 | $15.4M | $12.7M | +462.88% |
| 2012 | 2012-12-31 | $2.7M | −$2.7M | −49.80% |
| 2011 | 2011-12-31 | $5.5M | −$514,000 | −8.61% |
| 2010 | 2010-12-31 | $6.0M | — | — |
Oruka Therapeutics quarterly working capital
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $861.6M | $541.7M | +169.33% |
| Q1 2026 | 2026-03-31 | $378.6M | $38.3M | +11.24% |
| Q4 2025 | 2025-12-31 | $328.5M | −$35.3M | −9.71% |
| Q3 2025 | 2025-09-30 | $334.2M | −$60.7M | −15.37% |
| Q2 2025 | 2025-06-30 | $319.9M | $287.4M | +882.83% |
| Q1 2025 | 2025-03-31 | $340.4M | $305.3M | +869.99% |
| Q4 2024 | 2024-12-31 | $363.8M | $326.9M | +884.51% |
| Q3 2024 | 2024-09-30 | $394.9M | $357.0M | +941.98% |
| Q2 2024 | 2024-06-30 | $32.5M | −$6.6M | −16.87% |
| Q1 2024 | 2024-03-31 | $35.1M | −$5.3M | −13.22% |
| Q4 2023 | 2023-12-31 | $37.0M | −$4.6M | −11.10% |
| Q3 2023 | 2023-09-30 | $37.9M | −$4.7M | −11.06% |
| Q2 2023 | 2023-06-30 | $39.2M | −$5.7M | −12.69% |
| Q1 2023 | 2023-03-31 | $40.4M | −$7.4M | −15.44% |
| Q4 2022 | 2022-12-31 | $41.6M | −$9.4M | −18.37% |
| Q3 2022 | 2022-09-30 | $42.6M | −$13.9M | −24.56% |
| Q2 2022 | 2022-06-30 | $44.8M | −$16.3M | −26.60% |
| Q1 2022 | 2022-03-31 | $47.8M | −$18.0M | −27.38% |
| Q4 2021 | 2021-12-31 | $50.9M | $4.5M | +9.58% |
| Q3 2021 | 2021-09-30 | $56.5M | $6.1M | +12.05% |
| Q2 2021 | 2021-06-30 | $61.1M | $50.9M | +496.37% |
| Q1 2021 | 2021-03-31 | $65.8M | $59.6M | +958.17% |
| Q4 2020 | 2020-12-31 | $46.5M | $38.9M | +515.16% |
| Q3 2020 | 2020-09-30 | $50.4M | $41.7M | +475.84% |
| Q2 2020 | 2020-06-30 | $10.2M | $1.1M | +12.29% |
| Q1 2020 | 2020-03-31 | $6.2M | −$1.0M | −13.94% |
| Q4 2019 | 2019-12-31 | $7.6M | $1.6M | +26.24% |
| Q3 2019 | 2019-09-30 | $8.8M | $1.3M | +18.07% |
| Q2 2019 | 2019-06-30 | $9.1M | $174,000 | +1.94% |
| Q1 2019 | 2019-03-31 | $7.2M | −$3.8M | −34.31% |
| Q4 2018 | 2018-12-31 | $6.0M | −$4.2M | −41.50% |
| Q3 2018 | 2018-09-30 | $7.4M | −$6.4M | −46.40% |
| Q2 2018 | 2018-06-30 | $8.9M | −$5.2M | −36.69% |
| Q1 2018 | 2018-03-31 | $11.0M | −$6.3M | −36.50% |
| Q4 2017 | 2017-12-31 | $10.2M | −$8.8M | −46.30% |
| Q3 2017 | 2017-09-30 | $13.8M | −$7.8M | −36.06% |
| Q2 2017 | 2017-06-30 | $14.1M | −$10.9M | −43.54% |
| Q1 2017 | 2017-03-31 | $17.3M | −$11.3M | −39.54% |
| Q4 2016 | 2016-12-31 | $19.0M | −$18.4M | −49.08% |
| Q3 2016 | 2016-09-30 | $21.6M | −$18.8M | −46.43% |
| Q2 2016 | 2016-06-30 | $25.0M | −$17.9M | −41.73% |
| Q1 2016 | 2016-03-31 | $28.7M | $17.1M | +148.45% |
| Q4 2015 | 2015-12-31 | $37.4M | $23.3M | +165.33% |
| Q3 2015 | 2015-09-30 | $40.4M | $23.8M | +142.88% |
| Q2 2015 | 2015-06-30 | $43.0M | $24.5M | +132.74% |
| Q1 2015 | 2015-03-31 | $11.5M | −$9.1M | −44.20% |
| Q4 2014 | 2014-12-31 | $14.1M | −$1.3M | −8.58% |
| Q3 2014 | 2014-09-30 | $16.6M | −$1.6M | −8.85% |
| Q2 2014 | 2014-06-30 | $18.5M | −$1.4M | −7.26% |
| Q1 2014 | 2014-03-31 | $20.7M | $17.5M | +553.43% |
| Q4 2013 | 2013-12-31 | $15.4M | $12.7M | +462.88% |
| Q3 2013 | 2013-09-30 | $18.2M | $15.3M | +512.35% |
| Q2 2013 | 2013-06-30 | $19.9M | $16.8M | +550.38% |
| Q1 2013 | 2013-03-31 | $3.2M | −$943,000 | −22.96% |
| Q4 2012 | 2012-12-31 | $2.7M | −$2.7M | −49.80% |
| Q3 2012 | 2012-09-30 | $3.0M | −$2.4M | −45.11% |
| Q2 2012 | 2012-06-30 | $3.1M | −$3.8M | −55.14% |
| Q1 2012 | 2012-03-31 | $4.1M | — | — |
| Q4 2011 | 2011-12-31 | $5.5M | −$514,000 | −8.61% |
| Q3 2011 | 2011-09-30 | $5.4M | — | — |
| Q2 2011 | 2011-06-30 | $6.8M | — | — |
| Q4 2010 | 2010-12-31 | $6.0M | — | — |
Oruka Therapeutics working capital trends
Over the last five fiscal years, Oruka Therapeutics's working capital increased from $46.5M to $328.5M, a change of $282.0M. The latest reported quarter, Q2 2026, shows $861.6M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oruka Therapeutics source filings ↗Community posts
Oruka’s psoriasis study supports planned Phase 3 trials after strong skin clearance
Oruka ($ORKA) reported positive 16-week results for ORKA-001 in the randomized Phase 2b EVERLAST-B psoriasis study. Among 46 patients assigned the highest dose, 61% achieved complete skin clearance, compared with none of 47 placebo recipien ...
